Eliem Therapeutics, Inc. (NASDAQ:ELYM) Holdings Increased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 309.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,093 shares of the company’s stock after acquiring an additional 52,965 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Eliem Therapeutics were worth $357,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ELYM. Segall Bryant & Hamill LLC bought a new position in Eliem Therapeutics during the 3rd quarter valued at $297,000. Chicago Partners Investment Group LLC acquired a new stake in shares of Eliem Therapeutics in the third quarter valued at $81,000. SG Americas Securities LLC acquired a new stake in shares of Eliem Therapeutics in the third quarter valued at $60,000. Affinity Asset Advisors LLC bought a new position in Eliem Therapeutics during the second quarter valued at about $11,878,000. Finally, Ally Bridge Group NY LLC acquired a new position in Eliem Therapeutics during the second quarter worth about $3,555,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Eliem Therapeutics Trading Down 13.5 %

Shares of Eliem Therapeutics stock opened at $2.03 on Friday. Eliem Therapeutics, Inc. has a 52 week low of $2.35 and a 52 week high of $11.55. The company’s 50-day moving average price is $3.67 and its two-hundred day moving average price is $5.92. The stock has a market cap of $60.25 million, a PE ratio of -3.82 and a beta of -0.39.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.